Pular para o conteúdo principal
Ranking Invest

ALPN - Alpine Immune Sciences, Inc.

Segmento: HealthcareAlpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

Análise Ranking Invest

Valuation estimado
$ 171.99 Mi
Último Balanço Atualizado: 1T2024

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 332.70 Mi

Dívida Líquida

-$ 23.36 Mi

L4T

-$ 36.84 Mi

MM4T

-126.33%

Indicadores Básicos

ROE

-11.07%

Índices de Previsibilidade

Receita Líquida

F0.38

Lucro

C0.34

Margem

D0.58

Índices de Tendência

Receita Líquida

C7.00

Lucro

D-1.05

Margem

C2.02

Índices de Endividamento

DIV/PAT

-0.07

DIV/L4T

0.63

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.